Myositis Plasma

Myositis Plasma for Autoimmune Inflammatory Myopathy Research

Myositis Plasma is collected from IRB-consented donors clinically diagnosed with myositis and processed within one day of collection to preserve cytokines, autoantibodies, muscle-derived proteins and metabolites. Plasma is acellular, so this product is intended for soluble-analyte measurement rather than cell-based assays.

Myositis Autoimmunity and Why Plasma

The idiopathic inflammatory myopathies are autoimmune diseases of skeletal muscle, characterised by immune-mediated muscle injury, weakness and, in many patients, extramuscular involvement.

  • Myositis-specific autoantibodies define clinically meaningful subgroups, and their identification is now central to classification; anti-synthetase antibodies including anti-Jo-1, anti-Mi-2, anti-MDA5 and anti-TIF1-gamma are among the best characterised
  • Antibody specificity carries prognostic information: anti-MDA5 is associated with interstitial lung disease and anti-TIF1-gamma with malignancy risk, so serological subtyping genuinely changes study design
  • Type I interferon signalling is prominently upregulated in dermatomyositis, and interferon-inducible soluble mediators are measurable in circulation
  • Ongoing muscle fibre damage releases creatine kinase, aldolase, myoglobin and other muscle-derived proteins into plasma, providing quantitative disease activity readouts
  • Immune-mediated necrotising myopathy and inclusion body myositis have distinct mechanisms from the classical dermatomyositis and polymyositis groups, so subtype is not interchangeable
  • Plasma supports autoantibody immunoassays, muscle enzyme measurement, interferon signature-associated protein panels and proteomic discovery from a single acellular sample

Donor Stratification Available

  • Clinical subtype: dermatomyositis, polymyositis, immune-mediated necrotising myopathy, or inclusion body myositis
  • Myositis-specific autoantibody status where tested, including anti-Jo-1, anti-Mi-2 and anti-MDA5
  • Disease activity: active disease versus treated or in remission
  • Creatine kinase level at collection where available
  • Presence of interstitial lung disease or other extramuscular involvement
  • Treatment status: treatment-naive, on corticosteroids, on conventional immunosuppression, or on IVIG
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically confirmed myositis donors
  • Processed within one day of collection
  • IRB-approved protocols and informed consent
  • Custom aliquot volumes available upon request
  • Anticoagulant selection available on request to match your assay

De-identified Donor Data

  • Verified myositis diagnosis
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications, allergies, and comorbidities
  • Subtype and autoantibody results where available
  • Additional myositis-specific metadata available

Applications

  • Myositis-specific autoantibody detection and immunoassay development
  • Muscle injury marker measurement, including creatine kinase and myoglobin
  • Type I interferon-associated soluble mediator profiling
  • Inflammatory cytokine and chemokine quantification
  • Disease activity biomarker discovery and validation
  • Plasma proteomics and metabolomics in inflammatory myopathy
  • Immunosuppressive and biologic therapy response research
  • Subtype-resolved comparisons against matched healthy controls

Other Myositis Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Myositis plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse plasma from other disease states and check live stock status, visit our human plasma page.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 1–12 of 31 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information